It may be considered as a genetic modifying factor in pancreas cancer when it co-occurs with pathogenic BRCA1 variants, although this observation should be validated in a larger sample cohort of double heterozygotes. The gene discussed is BRCA1; the disease is pancreatic neoplasm.